Annovis Bio (ANVS) Stock Price, News & Analysis

Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key Stats

• Today's Range: $2.53 to $2.61
• 50-Day Range: $2.10 to $3.23
• 52-Week Range: $1.11 to $10.54
• Volume: 163,521 shs
• Average Volume: 287,986 shs
• Market Capitalization: $49.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Annovis Bio Stock Analysis - MarketRank™

Annovis Bio scored higher than 29% of companies evaluated by MarketBeat, and ranked 794th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Annovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Annovis Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Annovis Bio are expected to grow in the coming year, from ($2.19) to ($1.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annovis Bio is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annovis Bio is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annovis Bio has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.62% of the outstanding shares of Annovis Bio have been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Annovis Bio has recently increased by 4.24%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annovis Bio does not currently pay a dividend.

Dividend Growth

Annovis Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.62% of the outstanding shares of Annovis Bio have been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Annovis Bio has recently increased by 4.24%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Annovis Bio this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Annovis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.83% of the stock of Annovis Bio is held by institutions.

ANVS Stock Analysis - Frequently Asked Questions

How have ANVS shares performed this year?

Annovis Bio's stock was trading at $5.03 at the start of the year. Since then, ANVS stock has decreased by 49.1% and is now trading at $2.5590.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.15.

When did Annovis Bio IPO?

Annovis Bio (ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

Who are Annovis Bio's major shareholders?

Top institutional shareholders of Annovis Bio include Geode Capital Management LLC (0.94%) and Simplex Trading LLC.
View institutional ownership trends.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/09/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANVS
• CIK: 1477845
• Web: www.annovisbio.com
• Phone: 610-727-3913
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Annovis Bio: $18.00
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +603.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -300.56%
• Return on Assets: -193.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.68
• Quick Ratio: 10.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 19,490,000
• Free Float: 15,433,000
• Market Cap: $49.87 million
• Optionable: Optionable
• Beta: 1.51